# ERAvsCorona Action Plan: 10 priority actions

1. Coordination of R&I funding against the Coronavirus
2. ***Extending and supporting large EU wide clinical trials for clinical management of Coronavirus patients***
3. ***New funding for innovative and rapid health-related approaches to respond to coronavirus and deliver quick results relevant to society and a higher level of preparedness of health systems***
4. Increasing support to innovative companies
5. Creating opportunities for other funding sources to contribute to R&I actions on Coronavirus
6. Establish a one-stop shop for Coronavirus R&I funding
7. Establish an ad-hoc High Level R&I Task Force on the Coronavirus
8. Access to Research Infrastructures
9. Research data sharing platform
10. Pan-EU Hackathon to mobilise European innovators and civil society

European Commission

Research and Innovation

European Commission

# Portfolio analysis of EU R&I actions to combat COVID-19

Up till September 2020, dedicated COVID-19 H2020 calls (Health SC1 and other calls) disbursed **EUR 459 million** to **103 projects:**
- development of diagnostics, treatments, vaccines, epidemiology, preparedness;
- response to outbreaks, socioeconomics, production and digital technologies;
- infrastructures and data resources that enable this research.

EC RTD portfolio analysis has shown **547 projects** (funded by FP7 and H2020) with COVID-19 applications:
- scientific knowledge;
- solutions in e.g. new disinfectant coatings for protective clothing, in safely transporting patients, in waste water treatment and in digital applications.

*Overview:*
*https://ec.europa.eu/info/sites/info/files/research_and_innovation/research_by_area/documents/ec_rtd_coronavirus-research-projects-overview.pdf*

Research and Innovation

# Results of the Second 'Call for an Expression of Interest': budget € 128 million (Action 3 of the ERAvsCOVID-19 Action Plan)

- Implements the priorities outlined in action 3 of the ERAvsCorona Action Plan, in 4 areas.

- Uses similar process as 1st 'Expression of Interest' of January 2020 as the EU response to the COVID-19 pandemic, which led to the funding of 18 projects in March 2020.

European Commission

# Some examples of funded projects (starting Dec 2020 TBC)

**Theme A: Repurposing of manufacturing for vital medical supplies and equipment: IMPURE -** repurposing and digitally transforming plastic processing industrial lines for the production of critical medical consumables (PPE, ventilator accessories, fingertip pulse oximeter)

Theme B: Medical technologies, Digital tools and Artificial Intelligence (AI) analytics to improve surveillance and care at high TLR: **Innovation hubs with open calls to test and deploy rapidly emerging solutions and ideas addressing COVID-19**

Theme C: **Behavioural, social and economic impacts of the outbreak responses: RESPOND - Improving the** Preparedness of Health Systems to Reduce Mental Health and Psychosocial Concerns resulting from the COVID-19 Pandemic

**Theme D: Pan-European COVID-19 cohorts: ORCHESTRA**

**Theme E - Networking of existing EU and international cohorts of relevance to COVID-19: UNCOVER -** Unravelling Data for Rapid Evidence-Based Response to COVID-19

European Commission

Research and Innovation

# 2<sup>nd</sup> Expression of Interest SC1-PHE-CORONAVIRUS-2020

| Topic | Action type | Budget € million | Budget/ proposal € million | Proposals submitted |
|---|---|---|---|---|
| SC1-PHE-CORONAVIRUS-2020-2A - Repurposing of manufacturing for vital medical supplies and equipment | IA | 23 | 5-6 | 36 |
| SC1-PHE-CORONAVIRUS-2020-2B - Medical technologies, Digital tools and Artificial Intelligence (AI) analytics to improve surveillance and care at high Technology Readiness Levels (TRL) | IA | 56 | 2-5 | 221 |
| SC1-PHE-CORONAVIRUS-2020-2C - Behavioural, social and economic impacts of the outbreak responses | RIA | 20 | 4-10 | 162 |
| SC1-PHE-CORONAVIRUS-2020-2D - Pan-European COVID-19 cohorts | RIA | 20 | 15-20 | 21 |
| SC1-PHE-CORONAVIRUS-2020-2E - Networking of existing EU and international cohorts of relevance to COVID-19 | CSA | 3 | 2-3 | 14 |

Research and Innovation

# Our vision
## EU Wide Network based on Adaptive Platform Trials (APT)

**Network coordination**

Safety monitoring

Ethics

Harmonised protocols

PEARL* barriers

Study design

Prioritisation

APT1 coordination

APT2 coordination

APT3 coordination

APT4 coordination

APT5 coordination

**Adaptive Platform Trial 1**
- Therapeutic approaches 1: REMAP-CAP

**Adaptive Platform Trial 2**
- Therapeutic approaches 2: DisCoVeRy - based

**Adaptive Platform Trial 3**
- E.g. Immunoprophylaxis

**Adaptive Platform Trial 4**
- E.g. Vaccines

*Adaptive Platform Trial #*
- *Other, in response to new evidence*

**New therapeutic indications**

**New therapies**

**New clinical guidelines**

**New vaccines**

**EU Data Sharing Platform**

\* PEARL barriers: Political, ethical, administrative, regulatory and logistical barriers

European Commission

# Additional funding for EU wide COVID-19 clinical trials

- **EU-RESPONSE:** Adaptive platform trial to investigate several **treatment options** for **COVID-19 hospitalized patients (non ICU) –** based on *DisCoVery.*

- **RECOVER:** *Remap Cap* adaptive platform trial for **treatment options for ICU patients**

- **SUPPORT-E:** to coordinate efforts by gathering Member States initiatives to collect **convalescent plasma for treatment** purposes.

**Now on to vaccine trials….**